Drug Discovery & DDS– category –
-
Eli Lilly’s Foundayo (orforglipron) Receives FDA Approval, Ushering in a New Era of Oral GLP-1 RAs for Obesity Treatment
2 Minute Medicine USA Overview On April 1, 2026, Eli Lilly's Foundayo (orforglipron) gained FDA approval for obesity treatment, marking the first non-peptide oral GLP-1 receptor agonist without food or water timing restrictions. This bre... -
Nava Therapeutics Raises $89 Million for Lipid Nanoparticle (LNP) Platform: Innovating RNA Therapeutic Delivery
Endpoints News USA Overview Nava Therapeutics announced the completion of an $89 million Series A funding round to advance its lipid nanoparticle (LNP) platform, specialized in efficient RNA-based therapeutic delivery. This substantial f... -
BBB-Permeable Nanoparticles: A Novel Strategy for Breakthrough Neurodegenerative Disease Therapies
DovePress - International Journal of Nanomedicine UK Overview Research published in the 'International Journal of Nanomedicine' reports that the latest design of nanoparticles effectively crossing the blood-brain barrier (BBB) has brough... -
Boehringer Ingelheim Announces Promising Interim Phase 2 Results for Obesity Treatment BI 3034701: A Potential First-in-Class Triple Receptor Agonist
Boehringer Ingelheim Germany Overview Boehringer Ingelheim announced promising interim results from its Phase 2 clinical trial for BI 3034701, a novel triple receptor agonist for obesity. BI 3034701, targeting GLP-1, GCG, and GIP recepto... -
Generative AI Accelerates Industry Transformation: Innovative Drug Discovery Use Cases Expand in 2026
Masai School Blog India Overview A Masai School blog post highlights the expansion of innovative Generative AI use cases across diverse industries in 2026, with particular emphasis on its impact in drug discovery. The article reports tha... -
PharmTech Analyzes Mid-2026 Key Trends: AI Integration in Drug Discovery and Manufacturing, Strengthened Supply Chains, and New Drug Approvals
PharmTech USA Overview PharmTech released its 'Midyear 2026 Check-in' report, analyzing key pharmaceutical industry trends: AI integration in drug discovery and manufacturing, reinforced supply chain resilience, and new drug approval dyn... -
Exponential Progression in Targeted Protein Degradation (TPD) Drug Discovery: New Modality Accelerates Drug Development
MarinBio USA Overview MarinBio published an article highlighting the exponential progression in Targeted Protein Degradation (TPD) drug discovery, establishing it as a primary, accelerating modality in novel drug development. TPD technol... -
Clarivate Releases ‘Drugs to Watch in 2026’ List: AI Drug Discovery and DDS Technologies Highlighted as Promising Candidates
Clarivate UK Overview Clarivate released its mid-year 'Drugs to Watch' list for 2026, emphasizing that AI drug discovery and innovative drug delivery system (DDS) technologies are key trends driving the future market. The list includes A... -
The Critical Need for Human-Relevant Models in Drug Discovery to Accelerate Development with AI and Organoids
Technology Networks UK Overview This article discusses advancements in New Approach Methodologies (NAMs) in drug discovery, emphasizing their potential beyond the laboratory. It highlights the necessity for new training approaches and st... -
AI Accelerates Drug Discovery from Years to Days, Transforming Molecular Design and Generative Chemistry
Uplatz (YouTube) Unknown Overview This video discusses how AI is transforming drug discovery by accelerating molecular design, protein structure prediction, and generative chemistry, enabling molecule design in days. However, it highligh...
